What Johnson & Johnson's reusable contact lens is really defending

On September 10th Johnson & Johnson said it had received the CE mark for ACUVUE OASYS MAX 2-Week, a new reusable contact lens, and that it would reach a few European markets by the end of the year before a wider rollout through 2027-28. The headlines write themselves: a fresh innovation, a new approval, another launch. Read the product the way the company describes it, though, and something stranger emerges. This is a two-week lens, in a category the contact-lens industry has spent a decade steering its most profitable customers away from.

The world's 140m contact-lens wearers now split almost evenly between daily disposables and reusable lenses. The growth and the margins sit squarely with the dailies, which is why J&J's ACUVUE OASYS MAX line has been pushed so hard at 1-Day versions. Alcon, CooperVision and Bausch+Lomb are making the same bet; Reuters reported in February that after a sluggish 2025 the makers are banking on premium daily disposables to power a rebound. A company chooses to spend its engineering and regulatory effort on a reusable lens for one of two reasons: because it sees growth there, or because it fears losing ground there. For J&J, the second motive looks the stronger.

The clue is in the clinical detail. In testing, 99% of subjects already wearing ACUVUE OASYS 2-Week were refitted into the new lens on exactly the same power, base curve and diameter, with no extra chair time for the eye care professional. That is not a specification designed to win new wearers. It is a specification designed to move an existing customer from one J&J product to a pricier one without giving the optician a reason to reconsider the brand. Contact lenses are a switching-cost business — a prescription, a fitting, a habit, a loyalty to whoever wrote the order — and this launch protects that moat rather than extending it. The 60%-blue-violet-filter and moisture-locking claims are the garnish; the refit number is the argument.

Hence the cannibalisation that J&J must quietly accept. With a reusable MAX in the portfolio, the company now sells two versions of the same comfort story: a 1-Day daily at a premium price and a 2-Week reusable that captures the wearer who will not or cannot pay for dailies several times a week. Every reusable sale is, in part, a daily sale foregone. The company's logic is that better to take both slots than to let the price-conscious floater drift to a rival's monthly lens. It is a defensive hedge dressed as product-line expansion — understandable, and not obviously a growth story for the bottom line.

There is a second inversion, this one about geography. The CE mark clears the lens for Europe; it says nothing about the United States. The same announcement confirmed that the lens is not FDA-cleared and is not for sale in America. For a U.S. retail investor the direct-to-the-register effect of this news is, for now, exactly zero. Whatever revenue follows lands in Europe, on a slow autumn 2026 start and a two-year widening.

And the scale deserves a health warning of its own. J&J is a roughly $90bn-revenue company whose MedTech segment alone brought in $31.9bn in 2024; contact lenses are a sliver of a sliver. A CE mark for one lens in one segment is not, on its own, a reason to change a view of the shares. Its value is diagnostic rather than material: it tells the investor how the contact-lens oligopoly behaves when growth concentrates in dailies and the installed base of reusable wearers has nowhere else to go.

That is the durable lesson. The journalist's instinct is to cheer an approval; the analyst's is to ask what it defends. J&J's answer is a faithful retired base and a share price that is hard to dislodge — but also a business, for all its comforts, that must keep finding ways to justify a premium for products half the market already rejects by choice. A nice refit says nothing about whether the rent survives.